Skip to content

The effective dose of citrofol at different doses of sufentanil during induction of general anesthesia in non-elderly patients

Effect of Different Doses of Sufentanil on Effective Dose of Ciprofol During Anesthesia Induction in Non-elderly Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600127097
Enrollment
Unknown
Registered
2026-06-24
Start date
2025-09-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients requiring surgical treatment under general anesthesia.

Interventions

S1 group:0.1ug / kg sufentanil
S2 group:0.3ug / kg sufentanil
S3 group:0.5ug/kg sufentanil

Sponsors

Hangzhou Yuhang Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years, < 65 years; 2. The operation is required under general anesthesia; 3. American Society of Anesthesiologists (ASA) I-II; 4. Body mass index (BMI) was between 18-25 kg/m^2; 5. To sign an informed consent form indicating willingness to participate in the research process and voluntarily agree to be a subject.

Exclusion criteria

Exclusion criteria: 1. Allergic to propofol or have contraindications to the use of propofol (soybean allergy); 2. Preoperative disturbance of consciousness or chronic pain with long-term use of analgesics, psychotropic drugs (including opioids, NSAIDs, sedatives, antidepressants); 3. Expected difficult airway or abnormal anesthesia history; 4. Patients with tumor, severe cardiovascular and cerebrovascular diseases, etc.; 5. Sedatives, antiemetic drugs, antipruritic drugs, or monoamine oxidase inhibitors or antidepressants were used within 24 hours before surgery; 6. Researchers who do not agree to participate or are participating in other drug trials; 7. Emergency surgery.

Design outcomes

Primary

MeasureTime frame
ED50 of cycloprofen and their 95% confidence intervals;

Secondary

MeasureTime frame
Vital signs (BP, HR, SpO2);Pain intensity;Incidence of hypotension during induction;Incidence of bradycardia;Incidence of respiratory depression;Incidence of hypoxemia;Incidence of myoclonus;Incidence of postoperative nausea and vomiting;

Countries

China

Contacts

Public ContactQiu Yanzhen

Hangzhou Yuhang Second People's Hospital

18058793271@189.cn+86 571 57872167

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026